NO305203B1 - Oksazolidinonderivater, farmas°ytiske preparater som inneholder minst Ún slik forbindelse, og anvendelse av forbindelsene for fremstilling av legemidler - Google Patents

Oksazolidinonderivater, farmas°ytiske preparater som inneholder minst Ún slik forbindelse, og anvendelse av forbindelsene for fremstilling av legemidler

Info

Publication number
NO305203B1
NO305203B1 NO943523A NO943523A NO305203B1 NO 305203 B1 NO305203 B1 NO 305203B1 NO 943523 A NO943523 A NO 943523A NO 943523 A NO943523 A NO 943523A NO 305203 B1 NO305203 B1 NO 305203B1
Authority
NO
Norway
Prior art keywords
pharmaceuticals
compounds
manufacture
compound
oxazolidinone derivatives
Prior art date
Application number
NO943523A
Other languages
English (en)
Norwegian (no)
Other versions
NO943523L (no
NO943523D0 (no
Inventor
Joachim Gante
Horst Juraszyk
Peter Raddatz
Hanns Wurziger
Guido Melzer
Sabine Bernotat-Danielowski
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of NO943523D0 publication Critical patent/NO943523D0/no
Publication of NO943523L publication Critical patent/NO943523L/no
Publication of NO305203B1 publication Critical patent/NO305203B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/04—Amoebicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C07D263/24—Oxygen atoms attached in position 2 with hydrocarbon radicals, substituted by oxygen atoms, attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Adhesives Or Adhesive Processes (AREA)
NO943523A 1993-09-23 1994-09-22 Oksazolidinonderivater, farmas°ytiske preparater som inneholder minst Ún slik forbindelse, og anvendelse av forbindelsene for fremstilling av legemidler NO305203B1 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4332384A DE4332384A1 (de) 1993-09-23 1993-09-23 Adhäsionsrezeptor-Antagonisten III

Publications (3)

Publication Number Publication Date
NO943523D0 NO943523D0 (no) 1994-09-22
NO943523L NO943523L (no) 1995-03-24
NO305203B1 true NO305203B1 (no) 1999-04-19

Family

ID=6498425

Family Applications (1)

Application Number Title Priority Date Filing Date
NO943523A NO305203B1 (no) 1993-09-23 1994-09-22 Oksazolidinonderivater, farmas°ytiske preparater som inneholder minst Ún slik forbindelse, og anvendelse av forbindelsene for fremstilling av legemidler

Country Status (21)

Country Link
US (3) US5561148A (da)
EP (1) EP0645376B1 (da)
JP (1) JPH07179441A (da)
KR (1) KR100347849B1 (da)
CN (1) CN1052227C (da)
AT (1) ATE178599T1 (da)
AU (1) AU682050B2 (da)
CA (1) CA2132579A1 (da)
CZ (1) CZ288819B6 (da)
DE (2) DE4332384A1 (da)
DK (1) DK0645376T3 (da)
ES (1) ES2132295T3 (da)
GR (1) GR3030512T3 (da)
HU (1) HU217980B (da)
NO (1) NO305203B1 (da)
PL (1) PL180462B1 (da)
RU (1) RU2125560C1 (da)
SK (1) SK282134B6 (da)
TW (1) TW381086B (da)
UA (1) UA40590C2 (da)
ZA (1) ZA947405B (da)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4313411A1 (de) * 1993-04-23 1994-10-27 Basf Ag 3-Halogen-3-hetarylcarbonsäurederivate, Verfahren und Zwischenprodukte zu ihrer Herstellung
DE4332384A1 (de) * 1993-09-23 1995-03-30 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten III
DE4429461A1 (de) * 1994-08-19 1996-02-22 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
ATE170179T1 (de) * 1994-11-02 1998-09-15 Merck Patent Gmbh Adhäsionsrezeptor-antagonisten
DE4439846A1 (de) * 1994-11-08 1996-05-09 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
CA2208603A1 (en) * 1995-02-03 1996-08-08 The Upjohn Company Hetero-aromatic ring substituted phenyloxazolidinone antimicrobials
DE19516483A1 (de) 1995-05-05 1996-11-07 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
DE19524765A1 (de) * 1995-07-07 1997-01-09 Boehringer Mannheim Gmbh Neue Oxazolidinonderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
DE19601264A1 (de) * 1996-01-16 1997-07-17 Bayer Ag Pyrido-annellierte Thienyl- und Furanyl-Oxazolidinone
DE19601265A1 (de) 1996-01-16 1997-07-17 Bayer Ag 2-Oxo- und 2-Thio-1,2-dihydrochinolinyl-oxazolidinone
DE19601627A1 (de) * 1996-01-18 1997-07-24 Bayer Ag Heteroatomhaltige Cyclopentanopyridyl-Oxazolidinone
DE19604223A1 (de) * 1996-02-06 1997-08-07 Bayer Ag Neue substituierte Oxazolidinone
HRP970049A2 (en) 1996-02-06 1998-04-30 Bayer Ag New heteroaryl oxazolidinones
CN1478472A (zh) * 1996-07-25 2004-03-03 ¸ 细胞粘连抑制剂
EP0928194A4 (en) * 1996-08-29 2001-01-17 Merck & Co Inc COMPOSITIONS AND METHODS FOR ADMINISTRATING ANTAGONISTS OF THE INTEGRIN RECEPTOR
KR20010052615A (ko) 1998-06-05 2001-06-25 다비드 에 질레스 옥사졸리디논 유도체, 이것의 제조 방법 및 이것을함유하는 약학 조성물
GB9812019D0 (en) * 1998-06-05 1998-07-29 Zeneca Ltd Chemical compounds
CN1398189A (zh) 1998-12-23 2003-02-19 G.D.西尔公司 用于治疗肿瘤形成的放疗与cox－2抑制剂的联合治疗
GB9928568D0 (en) 1999-12-03 2000-02-02 Zeneca Ltd Chemical compounds
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
GB0009803D0 (en) * 2000-04-25 2000-06-07 Astrazeneca Ab Chemical compounds
DE10129725A1 (de) * 2001-06-20 2003-01-02 Bayer Ag Kombinationstherapie substituierter Oxazolidinone
DE10159453A1 (de) * 2001-12-04 2003-06-18 Merck Patent Gmbh Verwendung von 1-Phenyl-oxazolidin-2-on-Verbindungen als Protease
US7141588B2 (en) * 2002-02-25 2006-11-28 Pfizer, Inc. N-aryl-2-oxazolidinone-5-carboxamides and their derivatives
NZ535591A (en) * 2002-02-28 2006-07-28 Astrazeneca Ab Oxazolidinone derivatives, processes for their preparation, and pharmaceutical compositions containing them
DE10300111A1 (de) 2003-01-07 2004-07-15 Bayer Healthcare Ag Verfahren zur Herstellung von 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid
DE10355461A1 (de) 2003-11-27 2005-06-23 Bayer Healthcare Ag Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
JP2008512097A (ja) * 2004-09-07 2008-04-24 アーケミックス コーポレイション アプタマー医薬品化学
JP2008512098A (ja) 2004-09-07 2008-04-24 アーケミックス コーポレイション フォン・ビルブラント因子に対するアプタマー、および血栓性疾患の処置剤としてのその使用
US7566701B2 (en) * 2004-09-07 2009-07-28 Archemix Corp. Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics
DE102004062475A1 (de) * 2004-12-24 2006-07-06 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung
EP1685841A1 (en) 2005-01-31 2006-08-02 Bayer Health Care Aktiengesellschaft Prevention and treatment of thromboembolic disorders
DE102005045518A1 (de) 2005-09-23 2007-03-29 Bayer Healthcare Ag 2-Aminoethoxyessigsäure-Derivate und ihre Verwendung
DE102005047561A1 (de) 2005-10-04 2007-04-05 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit schneller Wirkstofffreisetzung
PT1934208E (pt) 2005-10-04 2011-06-01 Bayer Schering Pharma Ag Nova forma polimorfa de 5-cloro-n-({(5s)-2-oxo-3-[4-(3- oxo-4-morfolinil)-fenil]-1,3-oxazolidin-5-il}-metil)-2- tiofenocarboxamida
DE102005047558A1 (de) * 2005-10-04 2008-02-07 Bayer Healthcare Ag Kombinationstherapie substituierter Oxazolidinone zur Prophylaxe und Behandlung von cerebralen Durchblutungsstörungen
DE102006051625A1 (de) * 2006-11-02 2008-05-08 Bayer Materialscience Ag Kombinationstherapie substituierter Oxazolidinone
WO2008150495A2 (en) * 2007-06-01 2008-12-11 Archemix Corp. Vwf aptamer formulations and methods for use
JP5539221B2 (ja) 2007-12-21 2014-07-02 リガンド・ファーマシューティカルズ・インコーポレイテッド 選択的アンドロゲン受容体モジュレーター（ｓａｒｍ）およびその使用
AU2009206658A1 (en) * 2008-01-24 2009-07-30 Merck Sharp & Dohme Corp. 3,5-substituted-1,3-oxazolidin-2-one derivatives
ES2864079T3 (es) 2014-05-30 2021-10-13 Pfizer Derivados de carbonitrilo como moduladores selectivos del receptor de andrógenos
KR20220003554A (ko) 2019-04-19 2022-01-10 리간드 파마슈티칼스 인코포레이티드 화합물의 결정질 형태 및 결정질 형태를 제조하는 방법
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE791501A (fr) * 1971-11-19 1973-05-17 Albert Ag Chem Werke Diamines cycliques n,n'-disubstituees et leur procede de preparation
FR2315925A1 (fr) * 1975-07-04 1977-01-28 Nippon Chemiphar Co Nouveaux derives de 5-benzyle-2-oxazolidone, leur procede de preparation et leur application en therapeutique
US4602093A (en) * 1984-02-08 1986-07-22 Merck & Co., Inc. Novel substituted imidazoles, their preparation and use
DE3723797A1 (de) * 1987-07-18 1989-01-26 Merck Patent Gmbh Oxazolidinone
CA1320730C (en) * 1987-10-16 1993-07-27 The Du Pont Merck Pharmaceutical Company Aminomethyl oxooxazolidinyl aroylbenzene derivatives useful as antibacterial agents
US5053393A (en) * 1988-07-20 1991-10-01 Monsanto Company Novel platelet-aggregation inhibitor
US5084466A (en) * 1989-01-31 1992-01-28 Hoffmann-La Roche Inc. Novel carboxamide pyridine compounds which have useful pharmaceutical utility
DE4005371A1 (de) * 1990-02-21 1991-08-22 Merck Patent Gmbh Oxazolidinone
DE4017211A1 (de) * 1990-05-29 1991-12-05 Merck Patent Gmbh Oxazolidinone
HU220601B1 (hu) * 1992-04-30 2002-03-28 Taiho Pharmaceutical Co. Ltd. Fenoxi-alkil-oxazolidin-származékok, eljárás előállításukra és ezeket tartalmazó gyógyszerkészítmények
US5532225A (en) * 1992-07-31 1996-07-02 Sri International Acyclic purine phosphonate nucleotide analogs as antiviral agents, and related synthetic methods
ATE181735T1 (de) * 1993-05-01 1999-07-15 Merck Patent Gmbh Substituierte 1-phenyl-oxazolidin-2-on derivate, deren herstellung und deren verwendung als adhäsionsrezeptor-antagonisten
IL109570A0 (en) * 1993-05-17 1994-08-26 Fujisawa Pharmaceutical Co Guanidine derivatives, pharmaceutical compositions containing the same and processes for the preparation thereof
DE4324393A1 (de) * 1993-07-21 1995-01-26 Merck Patent Gmbh 4-Aryloxy- und 4-Arylthiopiperidinderivate
DE4332384A1 (de) * 1993-09-23 1995-03-30 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten III
TW286317B (da) * 1993-12-13 1996-09-21 Hoffmann La Roche
DE4439846A1 (de) * 1994-11-08 1996-05-09 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
TW363051B (en) * 1995-08-31 1999-07-01 Mitsui Toatsu Chemicals Substituted amidine derivatives and platelet aggregation inhibitor containing the same

Also Published As

Publication number Publication date
ZA947405B (en) 1995-05-15
DK0645376T3 (da) 1999-10-18
CZ288819B6 (cs) 2001-09-12
PL305144A1 (en) 1995-04-03
DE59408068D1 (de) 1999-05-12
ES2132295T3 (es) 1999-08-16
AU7305094A (en) 1995-04-06
CN1106806A (zh) 1995-08-16
CN1052227C (zh) 2000-05-10
RU94034124A (ru) 1996-07-10
DE4332384A1 (de) 1995-03-30
UA40590C2 (uk) 2001-08-15
EP0645376B1 (de) 1999-04-07
CZ224794A3 (en) 1995-07-12
JPH07179441A (ja) 1995-07-18
CA2132579A1 (en) 1995-03-24
PL180462B1 (pl) 2001-02-28
EP0645376A1 (de) 1995-03-29
US6028090A (en) 2000-02-22
RU2125560C1 (ru) 1999-01-27
US5723480A (en) 1998-03-03
US5561148A (en) 1996-10-01
KR100347849B1 (ko) 2002-11-16
NO943523L (no) 1995-03-24
GR3030512T3 (en) 1999-10-29
AU682050B2 (en) 1997-09-18
HU217980B (hu) 2000-05-28
KR950008493A (ko) 1995-04-17
SK112194A3 (en) 1995-05-10
ATE178599T1 (de) 1999-04-15
SK282134B6 (sk) 2001-11-06
NO943523D0 (no) 1994-09-22
HU9402724D0 (en) 1994-12-28
HUT71233A (en) 1995-11-28
TW381086B (en) 2000-02-01

Similar Documents

Publication Publication Date Title
DK0645376T3 (da) Substituerede 1-phenyl-oxazolin-2-on-derivater, fremstilling deraf og anvendelse som adhæsionsreceptor-antagonister
NO301419B1 (no) 2-okso-5-oksazolidinmetylforbindelser, farmasöytiske preparater som inneholder slike, og anvendelse derav for fremstilling av legemidler
YU155290A (sh) Dusikove spojine
NO306720B1 (no) Sykliske ureaer og analoger som er anvendbare som retrovirale proteaseinhibitorer, farmasöytiske preparater omfattende disse og anvendelse av forbindelsene for fremstilling av farmasöytiske preparater
PH29926A (en) Carboxylic and sulfonic acid amides and pharmaceutical composition thereof
EP0632031A4 (da)
BR9503536A (pt) Composto processo para sua preparação seu uso e composição farmacêutica
NO302519B1 (no) Tiazolidinforbindelser som inneholder en kinongruppe, og farmasöytisk preparat
NO178660C (no) Analogifremgangsmåte for fremstilling av N-aryl-piperazinalkanamidforbindelser
MX9604338A (es) Benzoilguanidinas sustituidas, procedimiento para su preparacion, su utilizacion como medicamento o agente de diagnostico, asi como medicamento que las contiene.
DK14389D0 (da) Substituerede 3-aminosydnoniminer og farmakologisk acceptable syreadditionssalte deraf, deres fremstilling og anvendelse samt mellemprodukter ved fremstillingen
ATE69605T1 (de) Azolylpropenyl- und azolylmethyloxiran-derivate und diese enthaltende fungizide.
ATE41145T1 (de) Antikonvulsiermittel.
DE3377647D1 (de) 5-halovinyl-2'-deoxyuridine derivatives
SE8201098L (sv) Nya ergolinderivat, deras framstellning och farmaceutiska kompositioner derav
ES2058458T3 (es) Inhibidor de la formacion de la placa dental.
NO842003L (no) Substituerte isokinolinderivater
DK20886D0 (da) Imidazolderivater, deres fremstilling og terapeutiske anvendelse
DK143991A (da) Syreadditionssalte af optisk aktive alaninanilidforbindelser og farmaceutiske praeparater indeholdende disse
ATE101119T1 (de) Butensaeure-amide, deren salze, diese enthaltende pharmazeutische zusammensetzungen und verfahren zu deren herstellung.
GB1527941A (en) 1-(3-phenylpropyl)-4-(beta-alkoxyacryloyl)piperazine derivatives
FR2396739A1 (fr) 1-aminomethyltricyclo(4.3.1.12,5)undecane et ses sels d'addition d'acide
DE69011174D1 (de) Catecholaminester.
DK84785A (da) Kinatsalte af antimalariaforbindelsen mefloquin

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees